Literature DB >> 7547430

Different effect of cyclosporin A on arthritides induced by a muramyl dipeptide analogue or the complete adjuvant in rats.

T Sugawara1, S Takada, K Furuhama, S Takayama, M Nomura, M Kato.   

Abstract

Muramyl dipeptide-Lys(L18) given by daily subcutaneous injection for 14 days induced arthritis in male Lewis, Fischer and nude rats, to a lesser degree in the last two than in the first strain. On the other hand, a single intradermal administration of Freund's complete adjuvant induced arthritis in Lewis and Fischer but not nude rats. Cyclosporin A (CsA) co-administered for 14 days markedly exacerbated the muramyl dipeptide-Lys(L18) induced arthritis (MIA) in rats of all three strains, but completely blocked the development of the adjuvant induced arthritis (AIA) in Lewis rats. Furthermore, AIA was transferred to recipient Lewis rats through spleen cells obtained from the donors with AIA, whereas MIA was not. Antibodies against type II collagen and DNA were not detected in sera from MIA or AIA rats. These data show a clear difference between MIA and AIA in the pattern of development of arthritis and suggest that delayed hypersensitivity reactions may be involved in the pathogenetic mechanisms of AIA, but not in MIA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7547430      PMCID: PMC1997172     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  35 in total

1.  A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats.

Authors:  E M Sternberg; W S Young; R Bernardini; A E Calogero; G P Chrousos; P W Gold; R L Wilder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

2.  Specific binding sites of muroctasin on murine macrophages.

Authors:  M Akasaki; H Masayasu; W Tsukada; T Takegoshi
Journal:  Arzneimittelforschung       Date:  1988-07

3.  Restorative activity of muroctasin on leukopenia associated with anticancer treatment.

Authors:  E Tsubura; T Nomura; H Niitani; S Osamura; T Okawa; M Tanaka; K Ota; H Nishikawa; T Masaoka; M Fukuoka
Journal:  Arzneimittelforschung       Date:  1988-07

4.  Production of interleukin-6 from macrophages by MDP-Lys (L 18), romurtide.

Authors:  K Shimoda; S Okamura; N Harada; F Omori; Y Niho
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1990-12

5.  Stimulation of macrophages by muroctasin to produce colony-stimulating factors.

Authors:  K Akahane; F Yamaguchi; Y Kita; T Une; Y Osada
Journal:  Arzneimittelforschung       Date:  1990-02

6.  Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats.

Authors:  E M Sternberg; J M Hill; G P Chrousos; T Kamilaris; S J Listwak; P W Gold; R L Wilder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

7.  Muroctasin [MDP-Lys(18)] augments the production of granulocyte colony-stimulating factor (G-CSF) from human peripheral blood mononuclear cells in vitro.

Authors:  K Shimoda; S Okamura; C Kawasaki; F Omori; T Matsuguchi; Y Niho
Journal:  Int J Immunopharmacol       Date:  1990

8.  Beneficial effect of muroctasin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.

Authors:  R Nakajima; Y Ishida; F Yamaguchi; T Otani; Y Ono; M Nomura; T Une; Y Osada
Journal:  Arzneimittelforschung       Date:  1988-07

9.  Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans.

Authors:  W van Eden; J Holoshitz; Z Nevo; A Frenkel; A Klajman; I R Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

10.  Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.

Authors:  O Kohashi; Y Kohashi; N Shigematsu; A Ozawa; S Kotani
Journal:  Lab Invest       Date:  1986-09       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.